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INVESTIGATING THE EFFECTS OF ENVIRONMENTAL MICROBIAL 
 





 Sepsis, a life-threatening organ dysfunction caused by dysregulated host immune 
response to infection, is one of the leading causes of death within intensive care units 
(ICUs) in the United States. Developing specific therapies to treat sepsis is a current 
challenge for translational research, where over 100 drugs developed to target pro- and 
anti-inflammatory pathways in sepsis have failed to pass clinical trials. The recent 
challenge in translating effective sepsis pharmaceuticals from animals to humans has led 
some researchers to question the overall viability of using specific pathogen free (SPF) 
mice as an animal model for sepsis in human beings. SFP mice are raised in a barrier 
facility designed to prevent exposure to specific pathogens, while humans are exposed to 
a wide range of pathogens on a daily basis. Acknowledging the influence that prior 
environmental pathogen exposure has on the immune system’s response to future 
infections, researchers have developed the cohoused (CoH) mouse model as a potential 
alternative to SPF mice for use in research on immunological diseases such as sepsis. 
CoH mice are SPF mice cohoused with “dirty” pet store mice for 60 days, which 
increases their pathogen exposure and results in mice with immune experience more 
comparable to humans. Although the CoH model shows promise, a recent study 
conducted by Huggins et al shows increased sepsis-induced morbidity and mortality of 
	 	 vii	
CoH mice compared to SPF mice when using the lipopolysaccharide (LPS) and cecal 
ligation and puncture (CLP) models of sepsis.  
 The experiments described in this thesis aim to further compare the inflammatory 
response of SPF, CoH, and pet store mice after intra-peritoneal injections of either LPS or 
cecal slurry (CS) to identify potential differences among these mouse groups and better 
understand why CoH mice experience increased mortality during sepsis. A baseline 
experiment was performed on each of these mice groups for comparison. Our baseline 
experiments demonstrate significant elevations in peritoneal immune cells within CoH 
mice compared to SPF mice. CS experiments demonstrate a significantly higher 
infiltration of immune cells in CoH mice following cecal slurry injection compared to 
SPF mice, suggesting that environmental pathogen exposure influences host 
inflammatory response within the peritoneum. However, LPS experiments were largely 
inconclusive. No significant differences were observed between SPF and CoH mice in 
regard to immune cell infiltration within the peritoneum, while blood analysis showed 
significant elevations in Tumor Necrosis Factor alpha (TNFα) and Interleukin 6 (IL-6) 
with increasing environmental pathogen exposure. Since the inflammatory response 
within the peritoneum to LPS was not significantly different between SPF and CoH mice, 
future studies could expand upon these results by investigating other tissue compartments 
in SPF and CoH mice following LPS injection into the peritoneum to provide a more 
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I. Defining Sepsis 
 Sepsis is a complicated disease, and it is important to understand the terminology 
surrounding sepsis before discussing its epidemiology. For the past two decades, our 
understanding of sepsis has changed considerably, and these developments have naturally 
changed how sepsis is defined and also how common terms such as septic shock, 
bacteremia, and organ failure relate to sepsis. Prior to 2016, most literature on sepsis 
followed a definition set by Bone and colleagues at the ACCP/SCCM consensus 
conference in 1992. The ACCP/SCCM defined sepsis as a “systemic immune system 
dysfunction” and created the “systemic inflammatory response syndrome” (SIRS) criteria 
as a tool for clinicians to identify patients with sepsis.1 Patients presenting with 
symptoms of “systemic immune imbalance” were diagnosed with “sepsis”, and patients 
whose immune imbalance progressed to organ failure were diagnosed with “severe 
sepsis”. However, in the decades that followed, sepsis was discovered to be more than an 
inflammatory disease, and by the early 2000s it was becoming apparent that the SIRS 
score system had poor specificity for sepsis.2,3 Furthermore, broad clinical criteria for 
identifying “systemic immune dysfunction” in patients made it difficult for clinicians to 
accurately diagnose sepsis.  
 In 2016, the Third International Consensus for Sepsis (Sepsis-3) examined fifteen 
years of research on the disease and recommended a new definition for sepsis. The 
Sepsis-3 task force redefined sepsis as a “life threatening organ dysfunction caused by a 
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dysregulated host response to infection” and provided a specific set of clinical criteria to 
identify the disease.4 In addition, the task force created a modified scoring system, the 
“quick sequential organ failure assessment” (qSOFA), as a diagnostic aid for clinicians to 
screen patients for sepsis. The Sepsis-3 definition for sepsis shared many similarities to 
the term “severe sepsis”, and this older term was concluded to be redundant with Sepsis-
3’s new definition. The committee discouraged its continued use. Sepsis-3 argued that 
including organ failure as part of diagnosing sepsis would improve sepsis identification 
and patient outcomes. 
 In addition to these improvements, Sepsis-3 also sought to clarify “septic shock” 
and other common terms surrounding sepsis. While limitations to the ACCM/SCCM’s 
definition of septic shock were recognized by 2001, a better alternative was never 
officially set for the term, and by 2016 multiple definitions for septic shock were in use. 
Sepsis-3 decided to define septic shock as “a subset of sepsis in which particularly 
profound circulatory, cellular, and metabolic abnormalities are associated with a greater 
risk of mortality than with sepsis alone”.4 The committee concluded that an inclusion of 
cellular and metabolic abnormalities to a definition for septic shock would help avoid 
overlap with general cardiovascular dysfunction. A set of clinical criteria was provided 
for identifying septic shock. Furthermore, the committee concluded that common terms 
such as “bacteremia” and “organ dysfunction” only describe certain aspects of sepsis and 
do not serve as synonyms for the disease. Other terms such as “septicemia” were 
considered nonspecific, and discouraged from use. Overall, Sepsis-3 significantly 
changed the classification of sepsis; changing its classification from a spectrum that 
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progressed from “sepsis” to “severe sepsis”, and “septic shock”, into a one-term 
classification focused on “sepsis” and a subset of sepsis: “septic shock”. Sepsis-3’s new 
framework for sepsis terminology aims to provide clear and up-to-date terms for a 
discussion on the disease. 
 This thesis will follow Sepsis-3’s definition for sepsis; using the word “sepsis” to 
describe the event of organ failure caused by a systemic, imbalanced immune response to 
infection. Most pre-2016 epidemiological studies follow the ACCP/SCCM definition for 
sepsis, and these studies will often make a point to differentiate between cases of “sepsis” 
and “severe sepsis”, where “sepsis” is defined as systemic immune system dysfunction 
and “severe sepsis” is immune system dysfunction with organ failure. However, under 
the new Sepsis-3 definition, this distinction is unnecessary. Since organ failure is now 
required for someone to be diagnosed with sepsis, any “severe sepsis” cases reported 
before 2016 will be interpreted as legitimate cases of sepsis for this thesis, while cases of 
“sepsis” excluding organ failure will be scrutinized. Although the recommendations of 
Sepsis-3 are not without their own critics, Sepsis-3 provides an up-to-date standard for 
the discussion of sepsis epidemiology, and as an international conference, reflects the 







II. Sepsis epidemiology 
Rates of incidence and mortality for sepsis: 
 Sepsis is a leading cause of death in intensive care units (ICUs) across the United 
States, and remains one of the highest financial costs for healthcare systems nationwide. 
In the United States, the CDC estimates that at least 1 in 3 people who die in a hospital 
die to sepsis, and sepsis is currently estimated to account for 1.7 million hospitalizations 
every year.5,6 A more recent dual cohort study by Liu et al, comparing patient data from 
over 1074 hospitals nationwide, suggests that sepsis accounts for an even greater share of 
inpatient mortality. They estimated that 34.7-55.9% of inpatient deaths in the US between 
2010 and 2012 were due to sepsis.7 Furthermore, Liu et al found that the majority of 
patients who died to sepsis in the ICU also presented with sepsis at the time of their 
admission; an unfortunate fact that underscores the current challenge modern healthcare 
systems have in treating the disease. Sepsis is a common occurrence within ICUs. Within 
the developed world, studies estimate that sepsis accounts for as much as 32% of patients 
admitted to ICUs.8,9 In the United States, the ICU incidence rate for sepsis is higher than 
many other well known diseases such as myocardial infarction, congestive heart failure, 
stroke, and pneumonia.10 
 Global estimates for sepsis incidence and mortality are limited by a general 
absence of epidemiological data on sepsis. A recent meta-analysis on the global impact of 
sepsis reported that “population level epidemiological data for sepsis was scarce to non-
existent in 2nd and 3rd world countries”.11 Of the 15 international citation databases 
searched, adequate epidemiological data for sepsis was available in only 7 countries. 
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These countries were all noted to have well-established public health and healthcare 
systems. When sepsis incidence and mortality rates from these countries were applied to 
the rest of the world, the global incidence of sepsis was roughly estimated to be 10.7 
million cases per year, and the global mortality was predicted to be 5.3 million deaths per 
year.11 However, true global incidence and mortality rates are most likely to be greater 
than these estimates. Within countries with poor sanitation, limited public health systems, 
and underequipped healthcare systems, sepsis incidence and mortality rates are most 
likely higher than the rest of the world. With roughly 87% of the world’s population 
unaccounted for, global sepsis epidemiology remains incomplete, and more work towards 
strengthening public health systems in developing countries may be necessary before an 
accurate estimation of sepsis’ global impact can be established.  
 Recent studies show that sepsis incidence in the United States is increasing while 
in-hospital morality for sepsis and septic shock is decreasing. In 2015, it was reported 
that the incidence of sepsis increased from 346/100,000 to 436/100,000 cases between 
2008 and 2012.12 On the other hand, in-hospital mortality for sepsis decreased over the 
same 5-year period, dropping from 22.2% to 17.3%.12 In-hospital mortality for septic 
shock was also reported to decrease around a similar time period. Between 2005 and 
2014 the hospital mortality for septic shock dropped from 48.3%-54.7% to 39.3-50.7%.13 
These downward trends in mortality may reflect improvements in intensive care (end 
goal directed therapy), increased public recognition (Surviving Sepsis Campaign), and 
better tools for early recognition of sepsis. Furthermore, the increase in sepsis incidence 
could be related to an aging baby boomer generation. As this larger generation continues 
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to age and life support facilities improve, it is natural to expect that the geriatric 
population will increase and incidence rates for sepsis with it.  
 However, there is some dispute over whether the increasing incidence and 
decreasing mortality rates for sepsis are accurate. In a 2016 study reviewing medical 
records from US hospitals, Gohil et al noted that increases in sepsis incidence and 
decreases in mortality were associated with the implementation of a new ICD-9 code for 
sepsis.14 These changes in medical coding for sepsis lowered the requirements for sepsis 
diagnosis, and were also argued to create financial incentives for doctors to diagnose 
sepsis; overall inflating incidence rates for sepsis and creating misleading trends in 
mortality.14 Varying inclusion criteria for sepsis within epidemiological studies is also 
cited as a potential confounder to the observed trends in sepsis incidence and mortality. 
Gaieski et al found that estimates for the annual incidence of sepsis could change up to 
3.5 times in magnitude depending what criteria was being used, with estimates ranging 
from 300/100,000 individuals to 1,031/100,000 individuals based on what codes they 
included when screening patient records for sepsis.15 In other cases, the use of diagnosis 
codes to identify sepsis is noted to underreport the actual number of sepsis cases. 
Criticism over the accuracy of current estimates for sepsis are supported by a recent study 
which reports no significant change in incidence or mortality rates for sepsis between the 
years of 2009 and 2014.16 Although trends in sepsis incidence and mortality rates are 
disputed, overall mortality and incidence rates are high, and sepsis is widely considered 




National Costs for Treating Sepsis 
 Understandably, the high mortality and incidence rates for sepsis translate into 
high financial costs for healthcare systems. Sepsis is currently reported to be the most 
expensive condition to treat in United States. The disease was reported to account for 6.2 
percent of all U.S hospitalization costs in 2013 at $23.7 billion, in spite of being 
responsible for only 3.6 percent of hospital stays.6 Its annual cost is greater than serious 
conditions such as acute myocardial infarction, stoke, or congestive heart failure.10 
Furthermore, the financial costs for sepsis seem to be increasing, with annual costs 
reported to have increased by $8.9 billion between 2003 and 2007.5 ICUs have the 
highest demands placed on them by sepsis, and it is estimated that in some hospitals 
sepsis consumes as much as half of the total resources used in ICUs annualy.12 In the 
United States, each patient with sepsis is estimated to cost $18,244 on average.6 The high 
financial cost for treating sepsis is concerning when considered from a national 
perspective, as age is a well-established risk factor for acquiring sepsis, and the largest 
generation in the US is currently between 55-75 years of age.17  
Risk Factors for Sepsis 
 There are a number of risk factors related to sepsis, but age is perhaps one of the 
most commonly cited risk factors for sepsis. In 2001, a large-scale observational cohort 
study conducted in the US by Angus et al found that the incidence rate for sepsis in >85 
years old patients was over 100 times larger than the incidence rate for children above 4 
years old.18 When patient data was organized by age, a clear increase in sepsis mortality 
and incidence is observed for patients 60 years of age and older (Figure 1). In 1st world 
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countries, more than 60% of sepsis cases involve people 75 years or older.19,20 
Interestingly, a rise in sepsis incidence is also observed in children under 4 years of 
age.18,21 Internationally it is estimated that sepsis accounts for more than 8% of cases 
where a child under the age of 4 is critically ill.21 These age related trends in sepsis 
incidence and mortality are thought to be due in part to the underdeveloped immune 
systems of younger patients and natural immunosenescence observed in older patients. 
These factors place both populations at a higher risk for infection, and infection is a 
prerequisite for sepsis.22  
 
Figure 1: Sepsis incidence and mortality rates by gender and age cohort as reported by Angus et al in their 
2001 study using 6,621,559 patient discharge records. Sepsis incidence is lowest in children >4 years to 
adults as old as 40 and increases in children <4 years and adults 40 years and older. Sepsis mortality 




 In addition to age, the presence of chronic disease is also observed as a risk factor 
for sepsis. It is estimated that more than half of patients with sepsis present with one or 
more comorbidities, including cancer, congestive heart failure, kidney disease, AIDS, and 
diabetes.22 Chronic disease often involves inflammation, which diverts resources from the 
host’s immune system that could otherwise be committed to fighting off novel infections. 
The resulting increase in risk for infection by extension increases the risk for sepsis in 
patients with chronic illness.22,23 
 Chronic disease as a risk factor for sepsis provides some explanation for the 
relatively higher elevation of sepsis incidence in geriatric populations compared to the 
elevated sepsis incidence rates in pediatric populations under the age of 4. Natural 
immunosenescence in older populations increases the risk for older patients to acquire 
chronic diseases, which in turn increases their risk for infection and sepsis.22 The 
disproportionate burden of chronic disease among geriatric populations may contribute to 
their higher sepsis incidence rate relative to pediatric cases of sepsis, in spite of both 
groups demonstrating elevated incidence rates for sepsis when compared to patients aged 
between 5 and 55.18,23 
 Epidemiological studies have also found demographic and socioeconomic 
disparities in sepsis incidence and mortality. Early epidemiological studies on sepsis 
report that male patients experienced both higher incidence and mortality for sepsis when 
compared to female patient populations.24 Black and Hispanic populations also 
experience disproportionately elevated sepsis mortality and incidence when compared to 
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the general population, and as is common with so many other diseases, low 
socioeconomic status is associated with higher rates of sepsis incidence and mortality.24 
 
III: Sepsis Pathology: 
General Pathway to the Septic Immune Response 
 Sepsis is defined as organ failure due to a dysfunctional host immune response, 
and this immune response occurs when bacteria gain access to the blood.4 In a healthy 
patient, infections are confined to their origin by the host’s innate and adaptive immune 
response. Inflammation, a central part of the innate immune response, increases 
permeability and the expression of selectins and integrins on local endothelial cells, 
which encourages innate immune cells to infiltrate the area of infection and neutralize 
bacteria. Histamine release from mast cells causes vasodilation of local vasculature, 
which increases the surface area of blood vessels around the site of infection and 
enhances infiltration of immune cells.25 Each innate immune cell expresses general 
pattern recognition receptors (PRR), which recognize pathogen associated molecular 
patterns (PAMPs) located on bacteria. Recognition of PAMPs by innate immune cells 
such as macrophages and neutrophils leads to the elimination of recognized bacteria 
through phagocytosis.26 Simultaneously, antigen presenting cells (APCs) collect antigen 
from dead bacteria and migrate towards local lymph nodes, where the collected antigen is 
presented to lymphocytes residing there. Lymphocytes and their responses make up the 
adaptive immune system. When lymphocytes with a receptor specific to the antigen 
recognize antigen in the lymph node, these lymphocytes become activated and rapidly 
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proliferate, moving throughout the body and neutralizing remaining bacteria in an antigen 
specific manner. Lymphocytes eliminate pathogens through either cell mediated [T cell] 
or humoral [B cell] pathways.27 For most cases of infection, if the innate immune 
response does not kill off the infection, it will slow the growth of the pathogen long 
enough for the adaptive immune system to mount an antigen specific response.27 
However, in the event of an immuno-compromised patient, or cases where the infection 
involves a highly resistant strain of bacteria, the innate and adaptive immune responses 
may fail to neutralize an infection, and the bacteria have the potential to reach the 
bloodstream and move through the body. It is at this point that the dysfunctional immune 
response central to sepsis pathology can occur. 
The Septic Immune Response 
 The septic immune response is responsible for both the organ failure that 
characterizes sepsis, and a state of chronic immunosuppression observed in most patients 
who survive sepsis. When bacteria reach the bloodstream, a complicated multitude of 
interactions occur between the PAMPs expressed by bacteria and PRRs expressed by 
immune cells in the bloodstream and associated tissues.28 Activation of PRRs on 
leukocytes in the blood leads to increased transcription of genes encoding for both pro 
and anti-inflammatory cytokines. A simultaneous increase of pro and anti-inflammatory 
cytokine levels in the blood results, which is often referred to as a “cytokine storm”. The 
interaction between pro-inflammatory and anti-inflammatory effects that result from the 
cytokine storm is complex and not fully understood. However, a bimodal pattern in the 
body’s response to elevated cytokine levels is often observed during the host’s 
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dysfunctional septic immune response (Figure 2).29 The first phase of this response is 
characterized by systemic inflammation, and often results in organ failure.  
 
Figure 2: The bimodal model of cytokine response during sepsis. Graph displaying a proposed model 
for how patient immune response differs over time during sepsis relative to baseline immune activity.29 
Patient displays a pro-inflammatory response during initial onset of the cytokine storm and later becomes 
immunosuppressed with increased risk for infection and viral reactivation. Adapted from Hotchkiss et al.29 
 
 When bacteria enter the blood stream and cytokine levels rise, the effects of pro-
inflammatory cytokines predominate those of elevated anti-inflammatory cytokines in the 
blood, and a once local inflammatory response now occurs throughout the body, resulting 
in multiple phenomenon. Systemic vasodilation occurs, dropping the patient’s blood 
pressure to a dangerous level, while leukocytes increase the expression of fibrogenic 
mediators such as Tissue Factor, which activate molecular clotting pathways in the 
blood.30 The systemic activation of clotting pathways leads to the generation of micro-
clots in the bloodstream, resulting in a dangerous pathological state diagnosed as 
“disseminated intravascular coagulation” (DIC). Thrombocytopenia is common 
observation in patients with sepsis. Furthermore, endothelial dysfunction is observed, 
which results in lower expression of anticoagulation regulators such as activated protein 
C, tissue factor pathway inhibitor, and antithrombin, which sustains DIC and increases 
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the host’s risk for organ failure.31 The complement system also contributes to the initial 
pro-inflammatory response. Activation of complement anaphylatoxin c5a during sepsis 
leads to excitation of myeloid cells via interaction with the c5a receptor (c5aR) present on 
most myeloid cells.32 The c5a/c5aR interaction increases recruitment of immune cells, 
activation of platelets, and is also associated with endothelial dysfunction. 
 These symptoms decrease blood flow to major organs, and without intervention, 
the acute septic immune response can lead to sepsis, multi-organ failure sepsis, septic 
shock, and eventual death. The necrosis of tissues injured from lack of perfusion cause a 
release of “damage associated molecular patterns” (DAMPs) in the blood, and their 
interaction with PRRs on leukocytes further exacerbates the cytokine storm, which results 
in more damage to the patient’s organs.28 Neutrophils contribute to the release of DAMPs 
during sepsis, which are observed to collect on the endothelium of lungs and liver and 
autolyse, releasing neutrophil extracellular traps (NETs) as well as DAMPs.33 While this 
release of NETs may help to eliminate pathogens at a local level, widespread NETosis 
observed in the lungs and liver during sepsis may also contribute to patient mortality. 
Since NETosis involves the release of cytotoxic molecules, concentrated NETosis within 
the microvasculature of these organs may damage surrounding parenchymal tissue, and 
further the cytokine storm through continued release of DAMPs.  
 Unfortunately, serious complications are observed in patients who survive the 
initial pro-inflammatory response to sepsis. In the United States, research on the survival 
of patients after sepsis show that those who survive sepsis are at increased risk for 
secondary infection, readmission to a hospital for sepsis, and mortality the year following 
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diagnosis, and these observations are largely attributed to the chronic immunosuppression 
in these patients.34,35 Sepsis-induced immunosuppression is characterized by a sharp 
decrease in the number of adaptive immune cells, increased numbers of 
immunosuppressive regulatory cells, and impaired function in certain types of immune 
cells. Patients begin to develop an immune-compromised state at the onset of the 
cytokine storm, where widespread apoptosis of CD4+ and CD8+ T cells and B cells 
occurs. Studies report that those CD4+ T cell lymphocytes remaining after mass 
apoptosis display a Th2 immunosuppressive phenotype, and are inhibited in their immune 
function. Patients who survive sepsis often present with elevated levels of T regulator 
cells, elevated Th2/Th1 ratios, and anti-inflammatory cytokines.36,37 
 The innate immune system also contributes to the immunocompromised phase 
following sepsis. Neutrophils undergo apoptosis during sepsis and are observed to have 
impaired function following sepsis, with decreased production of cytotoxic granules and 
impaired cellular movement.38 However, the apoptotic event for neutrophils is observed 
to occur later and with a lower magnitude relative to the apoptosis observed in 
lymphocytes. The function of APCs is also observed to be hindered post sepsis. Dendritic 
cells undergo apoptosis and are observed to have reduced function in septic patients.39 
Monocytes and macrophages demonstrate increased tolerance to LPS in septic patients, 
decreasing their response to LPS following exposure and limiting presentation of the 
antigen to lymphocytes when captured.40 Furthermore, patient’s post sepsis demonstrate 
increased levels of myeloid derived suppressor cells and regulator T cells, which act to 




IV. Diagnosis and Treatments for Sepsis: 
Diagnosing Sepsis: 
 There is no gold standard for the diagnosis of sepsis. Sepsis is regarded as a 
clinical syndrome, where a countless number of combinations between host immune 
system and bacterial strain results in a similar set of symptoms in patients with sepsis. 
However, there is currently a lack of consensus as to what specific symptoms should be 
emphasized in the sepsis syndrome, and some generally accepted symptoms for sepsis, 
such as systemic inflammation, are difficult to measure in a clinical setting. As a result, 
current strategies for sepsis diagnosis typically involve a combination of assessments.  
 One standard method for sepsis screening is to draw blood from the patient to 
determine the presence of bacteria and measure serum lactate concentration. If serum 
lactate levels are found to be high in a patient, this could reflect increased lactate 
production via anaerobic glycolysis secondary to tissue hypoxia, or impaired lactate 
clearance by the liver and kidneys due to organ failure.41 For these reasons, an elevated 
serum lactate concentration in a patient suspected of infection can be a useful guide for 
clinicians to use when looking for sepsis in their patients. However, the use of lactate 
concentration for sepsis diagnosis is not absolute, as evidence for tissue hypoxia and 
organ failure is not exclusive to sepsis pathology. Furthermore, while the presence of 
bacteria in the blood is a reliable method for diagnosing sepsis in patients, the absence of 
bacteremia does not rule out the possibility of sepsis in a patient. Since the organ failure 
of sepsis is ultimately caused by a cyclical and dysfunctional host immune response to 
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original infection, this immune response can continue via continued release of DAMPs 
and inflammatory cytokines secondary to host tissue damage, in spite of clearing the 
original infection.28 For these reasons, care providers have implemented the use of 
clinical scores to determine the presence of systemic inflammation and organ failure in 
patients, as both symptoms are central to sepsis pathology. 
 A care provider’s assessment of sepsis will often involve the use of a clinical 
score, which is a list of specific symptoms and lab results commonly observed in patients 
experiencing some pathology. The purpose of a clinical score is to provide clinicians with 
a numerical value that corresponds to the risk a patient has for a disease or mortality. 
When the number of listed symptoms observed in a patient reaches a certain threshold, it 
suggests to the clinician that the patient is more likely to be in that pathological state. For 
sepsis, the most common clinical scores used are the SIRS, SOFA, and qSOFA scores. 
Each clinical score has its own set of specific criteria for evaluating a patient for sepsis.  
 The ACCP/SCCM created the SIRS clinical score for use in evaluating a patient’s 
risk for sepsis. The SIRS clinical score suggests a patient is at risk for sepsis if two or 
more of the following symptoms are observed: (1) Temperature >38°C or <36°C, (2) 
heart rate >90/min, (3) respiratory rate >20/min or PaCO2 <32 mm Hg (4.3 kPa), and (4) 
white blood cell count >12 000/mm3
 
or <4000/mm3 or >10% immature bands.1 The score 
is intended to aid in the identification of sepsis, and not as a method to confirm the 
presence of the disease. SIRS is widely used as a “level of clinical suspicion” for sepsis. 
 The European Society of Intensive Care and Emergency Medicine created the 
“sequential organ failure assessment” (SOFA) scoring system in 1994.42 The SOFA score 
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is determined by observing symptoms in 6 different areas: respiration, coagulation, liver, 
cardiovascular, nervous system, and renal. Each area has its own score ranging from 0-4 
from lowest to highest severity. The SOFA score is the sum of all 6 areas of interest, 
ranging from 0-24. While a direct translation between SOFA score and mortality risk is 
not available, its reported that a SOFA score ≥ 2 for a patient correlates with a 2 to 25 
fold increase in risk of mortality compared to patients with a SOFA score less than 2.43 
The SOFA score is intended to aid clinicians in severity assessment for organ failure. 
 
Table 1: Summary of specific criteria for each system used to calculate a SOFA clinical score. Adapted 
from Vincent et al42 
 Sepsis-3 created the qSOFA scoring system in 2016 as a screening tool to quickly 
assess a patient’s risk for mortality and organ failure. The qSOFA suggests a patient is at 
risk for increased mortality if two or more of the following symptoms are observed: (1) 
altered mental status with a Glasgow coma scale <15, (2) respiratory rate ≥ 22, or (3) 
systolic BP ≤100.4 The qSOFA was intended to be a replacement for SIRS in screening 
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patients for sepsis outside of the ICU. Sepsis-3 recommended the SOFA score for 
clinicians assessing patients with sepsis inside the ICU.4 Each scoring system comes with 
its own advantages and disadvantages. 
 The best diagnostic strategy for evaluating patients for sepsis most likely involves 
the use of all three of these scoring systems. In the years preceding Sepsis-3, the SIRS 
score system was critiqued as a screening tool for its low specificity for sepsis, and the 
long time required to complete lab tests involved in the SIRS score. Early evaluations of 
Sepsis-3’s qSOFA scoring system found the qSOFA had higher selectivity and specificity 
for sepsis, and the qSOFA was recommended by Sepsis-3 as a replacement for SIRS.4 
However, recent studies comparing SIRS to the qSOFA now show that the selectivity of 
SIRS for sepsis is slightly higher than qSOFA, suggesting SIRS is still a better triaging 
tool for patients suspected to have sepsis in spite of its lower specificity.44 The qSOFA 
was found instead to be a better tool for predicting in-hospital mortality for patients 
outside of the ICU when compared to SIRS.44 For evaluation of patients inside the ICU, 
where the best resources are available to clinicians and patient cases are often most 
serious, the SOFA score has better selectivity and specificity for sepsis than either SIRS 
or qSOFA. Overall, the poor specificity of SIRS makes the SOFA score system a better 
tool for clinicians in ICUs, while with resources and time permitting, the SIRS score 
system is still a slightly better tool for screening patients for sepsis outside the ICU. The 
qSOFA, SIRS, and SOFA score systems are ultimately secondary to a clinician’s overall 





 There is no standard cure for treating sepsis. Perhaps one of the most complicated 
aspects to developing drug therapies for sepsis is that multiple cytokines pathways 
contribute to the disease.46 The progression from infection to the organ failure in sepsis is 
not limited to one cytokine pathway, and with no single molecular pathway fully 
responsible for sepsis, finding a direct pharmacological treatment for the condition is 
limited at best.47 However, organ failure is treatable in the ICU, and clinicians utilize 
general therapies to avoid sepsis mortality through quick identification and symptom 
management, particularly organ failure following a sepsis diagnosis. Common strategies 
for treating sepsis involve the use of antibiotics, introduction of fluids to the 
cardiovascular system, and vasopressors. Since the mortality rate for a septic patient 
increases the longer their organ failure is left untreated, early identification and treatment 
for sepsis is becoming an important focus for treating sepsis.48,49 General movements 
within the critical care medical community push to standardize clinical protocols for 
sepsis and improve sepsis treatment and outcomes. One example of such movements 
would be the Surviving Sepsis Campaign (SSC).  
 The SSC is a collaboration between SCCM and the European Society of Intensive 
Care Medicine (ESICM), which aims to provide up-to-date guidelines for clinicians 
treating sepsis. SSC guidelines were updated in 2016, and to simplify their update for 
clinicians, the SSC provided two 3 hr and 6 hr “bundles” that list their recommendations 
for what clinicians should aim to accomplish for patients after sepsis is diagnosed. The 
SSC recommends a serum lactate level, administration of broad spectrum antibiotics, and 
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a fluid bolus of crystalloid at 30 mL/kg be administered within 3 hours of diagnosis.44 
Serum lactate levels indicate the levels of stress recently experienced by bodily tissues 
and may correlate with organ failure, while fluid administration is intended to reduce 
mortality by reducing the effects of hypotension in septic patients. Antibiotics eliminate 
the original infection. By 6 hrs the SSC recommends administration of vasopressors to 
keep mean arterial pressure above 65 mmHg and reassessment of organ perfusion using 
serum lactate concentration to evaluate the degree of organ failure in the patient.44  
 While these treatments act to address the organ failure involved in sepsis, the ICU 
is still limited in treating the underlying dysfunctional immune response that is 
responsible for sepsis. Patients who experience a dysfunctional immune response to 
bacteria in the blood will often continue to progress towards organ failure and death 
without intervention.45 To address this, the SSC recently released a one-hour bundle to 
reduce the time that septic patients are without intervention and minimize the time where 
bacteria have access to the blood stream.45 Alongside recommendations for therapy, the 
implementation of screening tools like the SIRS and qSOFA criteria in outpatient 
facilities can also increase the speed at which septic patients receive care and help reduce 
mortality. Overall it is reported that the implementation of SSCs guidelines in some parts 
of the United States has dropped sepsis and septic shock mortality to 10%.50 However, 
there are critics who question the overall effectiveness of using general therapies for 
sepsis without patient specific treatments, as well as the accuracy of clinical scores and 
lactate levels in sepsis diagnosis. 
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Table 2: Surviving Sepsis Campaign guidelines for 3 and 6 hours within sepsis diagnosis. Adapted from 
Postelnicu et al.51 
 
V. Research on Sepsis 
Current State of Research on Sepsis 
 The absence of an FDA approved drug for sepsis reflects current challenges in 
both basic and translational research on the disease. Within the field of basic research, the 
cytokine storm is an important part of sepsis that is not fully understood. The cytokine 
storm results from the interaction between a variety of host immune cells and PAMPs, 
and multiple molecular pathways are excited simultaneously. The resulting cytokine 
composition in a cytokine storm can change significantly depending on the host’s 
immunity, type of offending pathogen, number of pathogens, and presence of coexisting 
diseases. This complexity makes the goal to fully characterize the cytokine storm a 
considerable task, and raises questions on whether a catch-all, “magic bullet” therapy for 
septic patients is a realistic goal for research on the disease. An alternative approach to 
sepsis research is personalized medicine, where the specific cytokine presentation of a 
	
 22 
person’s disease is determined and a patient specific treatment is provided. Personalized 
medicine shows promise in addressing diseases that are patient/pathogen dependent, such 
as sepsis.52 However, there are practical considerations that limit the application of 
personalized medicine for patients, and bringing personalized medicine to the forefront of 
care for sepsis will require more research into sepsis to understand the full range of 
presentation for the disease. While improving our understanding of sepsis is important for 
developing therapies for the disease, the translation of effective therapies in animal 
models to clinical trials is also a clear challenge in research on sepsis. 
 Translational research on sepsis experienced a considerable setback in the last 15 
years, as the multiple drugs developed to target common inflammatory cytokine 
pathways in sepsis failed to pass clinical trials in humans. To date, over 100 drugs 
targeting pro-inflammatory cytokines are shown to improve symptoms of sepsis in 
animal models, decreasing overall mortality.47 However, every one of these drugs has 
failed to pass clinical trials in humans. These promising drugs for sepsis either show no 
efficacy or paradoxically worsen symptoms of sepsis in study participants. This 
concerning discrepancy between the results of animal studies and clinical trials 
demonstrates the need for more basic research on sepsis, and also raises questions about 







Traditional Model for Research on Sepsis 
 Since legitimate ethical concerns often prohibit researchers from involving human 
participants in their studies, animals have historically been used to model human diseases 
in research. Mice have a long history of use in research for modeling human diseases. 
Mice are practical for experimental use as they age much faster than humans, reproduce 
quickly, are cheap to obtain, and are also easy to feed and house for long term 
experiments.47 Mice also have many genetic and physiological similarities to humans that 
favor their use as a model. Mice share 40% of their nucleotide sequence with the human 
genome, and 90% of the genes shared by mice and humans are located at the same spot 
on their respective chromosomes.53 This genetic similarity is observed to carry over into 
strong physiological similarities between mice and humans. The similarity in immune 
response between humans and mice has allowed researchers to successfully test potential 
therapies for humans using mice as a model, and this benefit to using mice in research 
cannot be understated. Mice studies have a central role in understanding human disease in 
basic research, and in pharmaceutical development, mice experiments are the most 
common way that drug developers fulfill the FDA’s requirement for animal studies to 
prove a drug’s efficacy before clinical trials.54 
 The mouse model used for most research on sepsis is the specific pathogen free 
(SPF) mouse model. The SPF model involves raising and housing mice in a standardized 
environment that limits their exposure to specific environmental pathogens. Using SPF 
mice in experiments minimizes the presence of pre-existing infection within a tested 
mouse population, thus limiting this potential confounding variable in experiments 
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evaluating host immune response.55 As a standardized system for housing mice, the SPF 
model also allows researchers to use mice with the same environmental pathogen 
exposure for any given experiment, which both increases the reproducibility of 
experiments and improves coordination between researchers. Due to its benefits, the SPF 
mouse model is widely used and common to many fields of research. However, the recent 
failure of sepsis drugs in clinical trials has raised concerns about the quality of the SPF 
model in research on sepsis, as these drugs showed clear improvements to sepsis in SPF 
mice before testing in clinical trials.56 General limitations to using mice as an animal 
model for sepsis, as well as specific limitations to the SPF housing model in sepsis 
research have been reconsidered.  
 There are a number of general limitations to using mice as a model for humans in 
sepsis research. For one, many experiments on sepsis are completed using younger mice 
due to time considerations and the greater availability of younger mice for use in 
research.57 The use of younger mice in experiments on sepsis limits generalizability to 
adult human populations, who are most effected by the disease. Temporal differences in 
sepsis progression between mice and humans also limit the murine septic model. Sepsis is 
often reported to develop in mice over the course of an hour, compared to the hours to 
days of development observed within humans.47 Furthermore, the sanitary conditions and 
short life cycle of mice limits the number of comorbidities present in tested SPF mouse 
populations. While this may minimize comorbidity as a confounding variable in 
experiments on sepsis, it also limits the SPF model for sepsis, as comorbidities are 
commonly seen in patients with the disease.22  
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 Sepsis is a disease closely related to the host’s immune system, and there are 
species-specific differences in the innate and adaptive immune systems between mice and 
humans. In 2003, Doeing et al reported that the predominate blood leukocyte in mice is 
the lymphocyte, which differs from the most common circulating leukocyte in humans: 
the neutrophil.58 The neutrophil itself differs between mice and humans, with the human 
neutrophil expressing the host defense peptide defensin, while murine neutrophils do not. 
FcR receptor expression on leukocytes and antibody class switching differs between 
humans and mice, and T cell receptor signaling and co-stimulation differs as well. 
Gentile et al and Seok et al report evidence that the transcriptional response from 
leukocytes during sepsis is considerably different between mice and humans.59,60 These 
differences in immune cell function could result in differences in the cytokine storm and 
overall presentation of sepsis between mice models and humans. Overall, many of the 
above limitations to using SPF mice are either based in genetic differences between mice 
and humans, or require large systematic changes to the field of research. Neither are 
practical places to start when looking to improve animal models used for sepsis. 
However, the difference between the SPF model and humans in their environmental 
exposure to pathogens is both a considerable limitation to the SPF model and an area that 
could be realistically addressed.  
 A clear disadvantage to using SPF mice for experiments on sepsis is the 
difference in pathogen exposure between SPF mice and human beings. Humans are 
exposed to a far greater number of pathogens than SPF mice are, and there is a large 
variation in pathogen exposure for humans while SPF mice are exposed to a limited 
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variety of pathogens. This is a significant observation when attempting to generalize data 
from SPF studies to humans, since pathogen exposure influences the host’s immune 
system, and host immune response is central to sepsis pathology. In 2016, Beura et al 
found that the immune system of SPF mice was more analogous to neonate humans than 
adult populations that frequently experience sepsis, suggesting SPF sanitary housing 
conditions contribute to overall inexperienced immune systems in SPF mice.61 Altering 
the environment that SPF mice are housed in to increase pathogen exposure could 
minimize this difference in immune experience between SPF mice and human 
populations that typically experience sepsis, and perhaps improve the translation of 
developed sepsis pharmaceuticals from animal to clinical trials. 
The Cohoused Mouse Model 
 The cohoused mouse model is an alternative mouse model to the SPF model that 
has potential for producing experiments on sepsis with greater generalizability to humans. 
Cohoused mice are created from SPF mice by placing 8 SPF mice in a cage containing a 
pet store mouse for 60 days in order to expose them to the variety of commensal and 
pathogenic microbes present on that pet store mouse.61,62 The result is cohoused mice that 
have immune systems more experienced than SPF mice. The increased exposure of CoH 
mice to environmental pathogens results in a noticeable difference in immune cell 




Figure 3: Image providing a visual summary of the immunological differences between CoH and SPF 
mice. Adapted from Huggins et al.62 
 
 Differences between the immune systems of cohoused and SPF mice suggest a 
potential for cohoused mice to be used as an alternative to SPF mice in experiments on 
sepsis. SPF and CoH mice demonstrate differences in adaptive immunity. Beura et al 
report that the majority of T cells in SPF mice are naïve while most of the T cell 
compartment in CoH mice displays mature or memory phenotypes.61 Differences are also 
observed in the innate immune system. Innate immune cells of cohoused mice are 
reported to have increased expression of TLR4 and TLR2 compared to innate immune 
cells of SPF mice.62 Since the pathology of sepsis results from a cytokine storm response 
from the host’s immune system, the degree of immune experience is an important 
consideration to make comparing data between an animal model and human beings. 
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Cohoused mice display elevated pro-inflammatory cytokine levels and immune cells at 
baseline, and both of these factors could influence the severity of inflammatory response 
to bacteria in CoH mice.61  
Increased mortality experienced under the Cohoused model 
 The greatest barrier to using cohoused mice in experiments on sepsis is the high 
rate of mortality that CoH mice experience following the induction of sepsis. Huggins et 
al found that CoH mice have a significantly higher rate of mortality compared to SPF 
mice under the LPS endotoxemia model (90% CoH mortality vs. 35% SPF mortality) and 
CLP model (75% CoH mortality vs. 20% SPF mortality) (Figure 4).62 The increased 
mortality for CoH mice is thought to be due in part to a larger “cytokine storm” response 
from CoH mice relative to SPF mice when experiencing the presence of LPS or bacteria 
in the blood. Huggins et al also observed a spike in pro-inflammatory cytokines IFN-g 
IL6, TNFα, and IL-1b within the first 24 hours following CLP in CoH mice, while no 
spike was observed in SPF mice treated with CLP.62 Previous studies report an 
association between elevated IL-6 and TNFα concentrations and increased host mortality 








Figure 4: A) Graph plotting the percent survival of SPF (black) and CoH (green) mice and number of 
hours following intravenous administration of LPS. B) Graph plotting the percent survival of SPF (black) 
and CoH (green) mice and the number of days following CLP. Adapted from Huggins et al.62 
 
 Unaddressed, the increased mortality of CoH mice under CLP and LPS models 
would require researchers to substantially increase the number of cohoused mice used in 
experiments to account for increased mortality. Understandably, the additional cost and 
workload associated with increasing the number of cohoused mice for experiments may 
outweigh the benefit of obtaining data with increased applicability to humans. Working 
towards a better understanding of how CoH, pet store, and SPF mice respond to LPS 
could help find ways to address the increased mortality of CoH compared to SPF mice 










Techniques to induce sepsis in research: 
 In order to create a model for sepsis in research, a septic immune response must 
be produced in the animal’s bloodstream. There are three methods commonly used in 
research to induce a septic cytokine storm response in animals: the cecal ligation and 
puncture model (CLP), the cecal slurry model (CS), and the endotoxemia model.  
 CLP is the most common model for creating sepsis in mice. The model requires a 
surgical procedure that opens the animal’s peritoneal space, and isolates its cecum. Once 
the cecum is isolated, a needle is used to puncture the cecum and the animal is sutured 
back up.64 The puncture allows for commensal bacteria from the cecum to move into the 
peritoneal cavity, where they can then access the bloodstream through the lymphatic 
system, inducing a septic immune response. One of the advantages of the CLP model is 
the control it offers researchers. Changing the number of punctures or gauge of needle 
used for puncture can modify the intensity of the cytokine storm experienced by the 
animal model.64 However, a disadvantage to using this model is the time and resources 
required to perform a surgical procedure for each mouse treated in an experiment. 
 An alternative model to CLP is the cecal slurry model. The CS model involves the 
use of a donor mouse, which is euthanized and its cecal contents harvested at the 
beginning of an experiment.65 The cecal content is mixed with diluted dextrose to 
produce cecal slurry. This mixture is then introduced into recipient mice by intra-
peritoneal (IP) injection. Differences in mouse weight are accounted for by calculating an 
injection volume specific to each mouse that follows a mass ratio between cecal content 
and mouse mass. One advantage of the CS model is that it takes less time to complete 
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than the CLP model. Researchers can alter the level of immune response in the animal by 
changing the ratio of slurry to mouse weight.65 However, the CS model requires that one 
or two mice be sacrificed to provide cecal content for the slurry mixture every 
experiment, and these mice could have otherwise been included as test subjects in the 
experiment. 
 A final model for sepsis is the endotoxemia model. The endotoxemia model 
involves the IP injection of an inflammatory molecule, which directly interacts with the 
PRRs of innate immune cells to produce a cytokine storm response.66 Since it does not 
directly involve bacteria, the resulting immune response is sometimes referred to as 
“sterile inflammation”. The most common inflammatory molecule used for the 
endotoxemia model is lipopolysaccharide (LPS), which is a common PAMP expressed on 
the outside of many gram-negative bacteria. When LPS is introduced to the peritoneal 
space and blood, it interacts with innate immune cells by binding to toll-like receptor 4 
(TLR4), a common PRR expressed on the outside of innate immune cells.66  
 The endotoxemia model differs from the other models in its use of a single 
inflammatory molecule to induce sepsis. Using LPS to induce a cytokine storm 
eliminates the variation of immune response seen in other models due to the use of 
intestinal bacteria, which express multiple PAMPs in addition to LPS.66 While this could 
be seen as an advantage for researchers seeking to eliminate extra variables from their 
experiments, the use of a single PAMP to induce a cytokine storm could also limit data 
generalizability as the septic immune response in patients often occurs to a variety of 
PAMPs and is not limited to LPS. Furthermore, inducing sepsis through a bolus of LPS is 
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different in function from the natural progression of sepsis in humans, where sepsis is 
normally caused by a slow but steady stream of bacteria entering the cardiovascular 
system.47 Aside from these limitations, the use of LPS for the endotoxemia model is also 
critiqued in that humans are more sensitive to LPS than mice are, and LPS mouse 
experiments on sepsis may underappreciate the immune response of humans experiencing 
sepsis.67 However, the LPS endotoxemia model requires minimal preparation, and using 
LPS to induce sepsis allows researchers to simplify a complicated inflammatory response 
involving multiple bacteria down to the LPS/TLR4 receptor mediated inflammatory 
pathway. Overall, each of these models has its own advantages and disadvantages. For 
this thesis, experiments were completed on SPF, CoH, and pet store mice using both CS 





 The purpose of the experiments described in this thesis was to further examine 
and compare the responses of SPF, pet store, and cohoused mice to LPS and CS. While 
the CoH model has potential advantages over the traditional SPF model for sepsis 
experiments, Huggins et al observed that when CoH mice are used to model sepsis, these 
mice die at a significantly higher rate than SPF mice.62 Identifying areas where cohoused 
mice are different from SPF mice under the endotoxemia and cecal slurry model could 
explain this higher mortality observed in CoH mice. In addition, pathological differences 
found in the CoH septic model could provide an opportunity to develop solutions for the 
increased mortality in CoH, and allow for this mouse model to be used as a 
straightforward alternative to SPF mice in research on sepsis. 
 The experiments for this thesis aimed to address three general questions:  
1) Does increased environmental exposure to pathogens in cohouse mice lead to an 
observable increase in total cell number, neutrophil, and macrophage counts within the 
peritoneum of CoH mice compared to SPF mice?  
2) When challenged with a poly-microbial insult via intra-peritoneal cecal slurry 
injection, do CoH mice show any differences in immune cell number or composition 
within the peritoneum compared to SPF mice under the same conditions? 
 3) When challenged with a bolus containing a single stimulus via intra-peritoneal 
injection of LPS, do CoH mice show any difference in immune cell number or 







I. Mouse Populations for Experiments 
 SPF mice, CoH mice, and pet store (PS) mice were used for experiments. NCL-
C57BL/6NCR mice purchased from Charles River (Wilmington, MA) were housed and 
maintained in a specific pathogen free, parvo negative environment within Research 
Animal Resource’s (RAR) facilities at the University of Minnesota. CoH mice were 
produced in a BSL-3 facility at the University of Minnesota by grouping 8 SPF mice with 
one PS mouse in each cage and allowing cohabitation for 60 days. Pet store mice were 
obtained from various commercial pet stores in the Twin Cities area. All mice were 
maintained and housed in accordance with IACUC guidelines for humane use and care of 
laboratory animals. 
 
II. LPS Endotoxemia Experiments 
LPS administration 
 A septic response was produced in SPF mice, CoH mice, and PS mice following 
the LPS endotoxemia model. LPS-EB extracted from Escherichia coli was purchased 
from InvivoGen for use in experiments. Mice were administered a 10 mg/kg dose of LPS 
via intra-peritoneal injection. LPS dosage was characterized by a mass ratio: milligrams 
of LPS administered per kilogram of mouse weight, in order to maintain the same relative 
dose across all mice used for an experiment. Each mouse was individually weighed 
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before experiments were conducted, and these recorded masses were used to calculate 
individual LPS injection volumes. The appropriate injection volume for each mouse was 
calculated using the formula: [mass of individual mouse * desired dose of LPS / 
concentration of LPS stock solution = injection volume for individual mouse]. For the 
experiments in this thesis, the concentration of the LPS stock solution was arbitrarily set 
at 1 mg LPS per mL of stock solution. Control groups were used in each experiment and 
received intra-peritoneal injections of phosphate buffered saline (PBS). The highest 
injection volume calculated in the LPS treated group was used as the PBS injection 
volume for all controls. PBS injection volume for controls was not specific to the 
individual masses of each control mouse. Injections were performed under a class II 
biosafety cabinet. 
 Intra-peritoneal injections for LPS treatment and PBS control groups followed the 
same protocol. Mice were properly restrained in a supine position and their upper body 
was tilted back at a 30-degree angle to the horizontal axis to encourage the abdominal 
organs to move back and away from abdominal wall. The lower right quadrant of each 
mouse was punctured at a 30-40o angle from the horizontal axis using a 27-gauge needle 
and syringe containing either PBS or LPS stock solution. The needle was inserted bevel 
up, and after insertion the syringe was slowly pulled back to aspirate the needle before 
the appropriate injection volume was administered. After injection, each group was 








 A blood sample and peritoneal lavage were collected for both LPS treated mice 
and controls 6 hours after injection. Sample collection was performed under a class II 
biosafety cabinet. Blood samples were collected via a cheek bleed per University of 
Minnesota Research Animal Resources guidelines.68 To perform a cheek bleed, a mouse 
was restrained and their submandibular vein located at the base of their cheek. The area 
was then punctured with an 18-gauge needle to the depth of the bevel, and removed to 
allow blood flow. A micro-centrifuge tube was placed underneath the puncture wound, 
and 4-7 drops of blood were collected for analysis. After blood samples were collected, 
mice were euthanized in an environment containing oxygen and 5% isoflurane. Before a 
peritoneal lavage was performed, a toe pinch on each mouse was completed. 
 Peritoneal lavages were performed on each mouse and followed the same 
protocol. Following euthanasia, a mouse was sprayed with 70% ethanol and placed in the 
prone position. The outer skin of the lower back was cut at a 30-degree angle using 
forceps and pair of scissors, and the skin surrounding the incision was pulled back by 
gently tugging the base of the tail and skin above the incision. With the posterior surface 
of the peritoneal membrane exposed, the mouse was then placed in the supine position 
and any skin covering the anterior side of the peritoneal membrane was gently separated 
and pulled back. The mouse was mounted on a Styrofoam surgical block in the supine 
position, and a 27-gauge needle was used to inject 5 mL of an ice-cold lavage solution 
into the peritoneum. Lavage solution was made using 3% fetal calf serum, and 0.4% 
ethylenediaminetetraacetic acid (EDTA) in PBS. Injections for each peritoneal lavage 
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were done at a 30o angle to the horizontal axis. The 27-gauge needle was inserted in the 
lower right quadrant of the anterior peritoneum and aspirated before injecting 5 mL of 
lavage solution. Care was taken to avoid puncturing blood vessels or organs within the 
peritoneum during injection.  
 After injection of lavage solution, the peritoneum was gently massaged for 30 
seconds to suspend peritoneal cells in the solution. The surgical block was raised to tilt 
the block at a 40o angle and encourage lavage fluid within the peritoneum to move 
towards the right side of the mouse. A 25-gauge needle was inserted at the lower right 
quadrant of the peritoneum at a 30o angle to the horizontal, and peritoneal cells 
suspended in lavage fluid were collected into a clean syringe. The lavage sample was 
moved from a syringe into a 15 mL conical tube, and placed on ice to preserve the sample 
until it was time for sample preparation. This protocol was repeated for all mice in the 
experiment. Lavage samples containing blood were discarded and not included for data 
analysis. 
 
Blood Sample Preparation: 
 Collected blood samples were allowed to rest at room temperature for roughly 40 
minutes before samples were placed in a centrifuge for 10 minutes at 15,000 rpm. The 
supernatant was collected and placed in a centrifuge again for 10 minutes at 15,000 rpm. 






Lavage Sample Preparation: 
 Collected lavage samples were prepared for Fluorescence Activated Cell sorting 
(FACs) analysis. The following antibodies were used for myeloid staining in lavage 
samples: PE-conjugated anti CD115 (Tonbo Biosciences), PEcy7-conjugated anti CD11c 
(BioLegend), Alexa Fluor 700-conjugated anti F4/80 (BioLegend), APC-conjugated anti 
Ly6G (BioLegend), PerCPcy5.5-conjugated anti Ly6C (BioLegend), BV421-conjugated 
anti CD11b (BioLegend), BV605-conjugated anti MHCII (BioLegend), FITC-conjugated 
anti ICAM2 (BioLegend), biotinylated anti CD19 (BioLegend), and BV510-conjugated 
streptavidin (BioLegend). BV510 dye was used for a live dead stain (Tonbo Biosciences). 
A 1:50 dilution of rat serum and normal mouse serum was added to the staining master 
mix as a block. Cells from lavage samples were fixed in 2% paraformaldehyde solution. 
FACs buffer was used for all wash steps. Cells were suspended in FACs buffer and 
incubated at (5ºC) until their analysis the following morning on a flow cytometer. 
  A 10 µL aliquot was taken from each original sample and these cells were 
blocked and fixed for count tubes. Count tube cells were suspended in a (200,000 
beads/mL) counting bead mixture prepared from Invitrogen 123count eBead 
(1.03*106/mL) stock solution purchased from Thermo Fisher Scientific.  
 In each experiment a spleen was obtained from one control mouse to prepare 
compensation tubes for FACs analysis. Spleen cells were separated from organ 
connective tissue using a GentleMACS Dissociator (Miltenyi Biotec), and the resulting 
solution was passed through a 70 um nylon filter to isolate cells. ACK lysis buffer was 
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added to the filtered spleen sample to reduce erythrocytes present in splenocyte solution. 
Cells remaining in the splenocyte solution were used for compensation tubes. The 
following compensation antibodies were used for each respective compensation tube: 
BV510-conjugated anti B220 (BioLegend), Alexa Fluor 700-conjugated anti CD4 
(BioLegend), FITC-conjugated anti CD4 (Tonbo Biosciences), PE-conjugated anti CD4 
(eBioscience), PE cy7-conjugated anti CD4 (Tonbo Biosciences), BV605-conjugated anti 
CD4 (BD Biosciences), PerCP cy5.5-conjugated anti CD4 (Tonbo Biosciences), APC-
conjugated anti CD4 (BioLegend), and BV421-conjugated anti CD4 (BioLegend). 
 
III. Cecal Slurry Experiment: 
 A septic response was also induced in SPF and CoH mice following the cecal 
slurry injection model. SPF and CoH mice received peritoneal injections of cecal slurry 
instead of LPS, and lavage samples were obtained from mice 6 hours post injection 
following the same protocol used for LPS injection experiments. To create a cecal slurry 
solution, a donor mouse from each group was sacrificed and its cecal contents were 
collected. The cecal content was weighed using a scale, and a specific volume of 5% 
dextrose in PBS was added in order to produce a cecal slurry solution at the concentration 
of 40 mg/mL. Mice were pre-weighed for the experiment and specific injection volumes 
for cecal slurry administration were calculated to maintain a dose of 0.75 milligrams 
cecal content per kilogram of mouse mass across all mice within the cecal slurry 
treatment group. Controls received peritoneal injections of 5% dextrose in PBS. The 
injection volume for all controls was set as the highest injection volume received by a 
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member in the cecal slurry group. The injection volume for controls was not specific to 
the mass of each mouse. Peritoneal injections of CS were administered following the 
same protocol outlined above. Serum samples were not collected from mice involved in 
the cecal slurry experiment. 
 
IV. Baseline Lavage Experiments 
 A peritoneal lavage was performed on SPF, CoH, and PS mice without 
administering intra-peritoneal injections to compare degree of peritoneal cell presence 
between each group under baseline conditions. Peritoneal lavages followed the same 
protocol described above for both LPS and CS experiments. Serum samples were not 
collected for baseline experiments. 
 
V. Flow Cytometric Gating and Analysis of Prepared Samples 
 Stained lavage samples were analyzed on a Fortessa X-20 cytometer (BD 
Biosciences) using FACSDIVA software (BD Biosciences). Data read by the flow 
cytometer was recorded on FACSDIVA and exported to FlowJo software (Tree Star) for 
population gating and analysis. A gating scheme was used to gate all samples for both 
baseline (Figure 5) and LPS/CS treatment experiments (Figure 6). Flow cytometer data 
was gated in FlowJo for neutrophils, small peritoneal macrophages, and large peritoneal 
macrophages, and a population frequency was found for these three cell types in each 
sample. Flow cytometric data collected from count tubes was used to determine a total 
cell concentration for each sample. Cell-specific counts were calculated for each cell type 
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using the equation: (frequency of specific cell type in sample * 5 mL lavage solution * 
total concentration of cells per 5 mL sample = total number of specific cell type). Cell 
type frequencies, total cell concentration, and cell counts were organized for each sample 
and recorded on an Excel spreadsheet for all experiments.  
 
Figure 5: Gating scheme used within FlowJo software to determine the frequency of neutrophils, small 





Figure 6: Gating scheme used within FloJo software to determine the frequency of neutrophils, small 
peritoneal macrophages, and large peritoneal macrophages for each lavage sample acquired from treated 
mice. 
 
VI. ELISA Analysis 
 Serum concentrations for the two pro-inflammatory cytokines TNFα and IL-6 
were determined through “sandwich” Enzyme Linked Immunosorbent Assays (ELISA). 
The ELISA kits used to test serum samples for TNFα and IL-6 were standard kits 
purchased from BioLegend. Serum samples were taken from – 80°C storage, thawed on 
ice, and spun in centrifuge at 15,000 rpm before being added to ELISA plate. Activated 
ELISAs were stopped using sulfuric acid, and the finished ELISA plates were read using 
an Epoch Spectrophotometer purchased from BioTek. Data obtained from the 
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spectrophotometer was recorded on a computer using Gen5 micro-plate software 
purchased from BioTek.  
 
VII. Prism 6 Statistics on FACs and ELISA Results 
 Flow cytometry and ELISA results were graphed and statistically analyzed using 
Prism 6 software (GraphPad). Cell counts and cytokine concentrations were exported 
from excel into Prism 6, organized by mouse group, and linear values for cell count and 
cytokine concentration were transformed onto a log scale. Statistical significance was 
determined for ELISA and flow cytometric data using one-way ANOVA and Tukey’s 
multiple comparisons test within Prism 6 software. Statistical significance for a 
comparison of baseline SPM and LPM counts between SPF and CoH was calculated 
using an unpaired T test within Prism 6 software. Any comparison between groups with 











I. Baseline peritoneal cell counts are increased in CoH mice compared to SPF mice 
 Lavage samples were collected from untreated SPF and CoH mice. Collected cells 
were stained for neutrophils, small peritoneal macrophages (SPMs) and large peritoneal 
macrophages (LPMs). Samples were analyzed by flow cytometer following staining. A 
statistically significant difference in neutrophil (p=0.012), peritoneal macrophage 
(p=0.0061), and total peritoneal cell number (p=0.025) was observed between SPF and 
CoH mice at baseline (Figure 7). CoH mice were found to have an average 29,391 
neutrophils per 5 mL peritoneal lavage, compared to the average 5,344 neutrophils per 5 
mL in SPF mice, and 884,902 in PS mice (Figure 7B). CoH mice had a statistically 
significant lower count for neutrophils (p<0.0001) and peritoneal macrophages 
(p<0.0008) compared to PS mice (Figures 7B and 7C). A comparison of the baseline 
Figure 7: Total cell, neutrophil, and peritoneal macrophage counts between specific pathogen free mice 





























































































total cell number between CoH and PS mice found a similar trend, with PS mice 
displaying a higher average total cell number in the peritoneum compared to CoH 
(5,699,792 cells in CoH vs. 14,340,058 cells in PS) (Figure 7A). This difference between 
CoH and PS mice in total cell number at baseline was not statistically significant 
(p=0.098). CoH mice also demonstrated statistically significant elevations in small 
peritoneal macrophages (p=0.0461) and large peritoneal macrophages (p<0.0001) when 
compared to SPF mice (Figure 8). 
 
Figure 8: Large peritoneal macrophage (LPM) and small peritoneal macrophage (SPM) counts observed in 
SPF and CoH mice at resting state. CoH mice demonstrate significantly elevated LPM and SPM counts 
























































II. Peritoneal cell counts for SPF, CoH, and PS mice treated with LPS are 
inconclusive 
 Lavage samples were collected from SPF and CoH mice 6 hours after intra-
peritoneal injection of LPS. Collected cells were stained for neutrophils, SPMs, and 
LPMs. Stained samples were analyzed by flow cytometer. The average total cell number, 
SPM, and LPM counts were lower in LPS treated groups compared to their PBS control 
for SPF, CoH, and PS mice (Figure 9). This difference between LPS treatment and PBS 
control was not found to be statistically significant in SPF, CoH, or PS mice for total cell 
number (p=0.868, p=0.170, p=0.051), SPM count (p=0.887, p=0.266, p=0.068), or LPM 
count (p=0.899, p=0.165 p=0.162). 
 When comparing between LPS treated groups for trends in total cell number, 
SPM, and LPM counts, a downward trend in the average value for these counts was 
observed with increasing immune exposure (Figures 9A, 9C and 9D). LPS treated SPF 
mice (SPF[LPS]) demonstrate the highest average value for total cell number, SPM, and 
LPM counts, and LPS treated PS mice (PS[LPS]) had the lowest average values for each 
of these categories. The average value for total cell number, SPM, and LPM counts in 
LPS treated CoH mice (CoH[LPS]) was lower than the average values for SPF[LPS] and 
higher than average values for PS[LPS]. These differences between CoH[LPS] and 
SPF[LPS] mice in total cell number, SPM, and LPM counts were not found to be 




Figure 9: Total cell count, neutrophil, small peritoneal macrophage, and large peritoneal macrophage 
counts between SPF, CoH and PS mice treated with LPS and PBS.  
 
 The trend between LPS treated populations in neutrophil count deviated from the 
previously described trends for total cell number, SPM, and LPM counts. SPF[LPS] and 
CoH[LPS] groups demonstrated higher neutrophil counts compared to their respective 
controls, while neutrophil counts in PS[LPS] were lower than the neutrophil counts for its 
control (Figure 9B). These differences between LPS and PBS treated groups in 
neutrophil count were not found to be statistically significant for SPF (p=0.887), CoH 


















































































































































































































counts between LPS treated groups, CoH[LPS] was found to have a slightly higher 
average neutrophil count than SPF[LPS]. PS[LPS] displayed the lowest average 
neutrophil count. Differences between SPF[LPS] and CoH[LPS] and SPF[LPS] and 
PS[LPS] in neutrophil count were not found to be statistically significant (p=0.228 and 
p=0.533). 
 When comparing the degree of value variation between LPS treatment groups, 
PS[LPS] was observed to have a greater variation in its values for both total cell number 
and SPM counts relative to SPF[LPS] and CoH[LPS]. SPF[LPS] demonstrated slightly 
greater variation in its values for total cell number, SPM, and LPM counts compared to 
CoH[LPS]. No substantial difference was observed in the variation of values for 
neutrophil or LPM counts between all three LPS treated groups.  
 
III. Under septic conditions, CoH mice display higher average serum concentrations 
of pro-inflammatory cytokines compared to SPF mice  
 Blood samples were collected from SPF and CoH mice 6 hours after intra-
peritoneal injection of LPS. Serum was obtained from collected blood samples. Serum 
was tested on ELISA plate and results were analyzed using a spectrophotometer. The 
average values for TNFα and IL-6 serum concentrations were higher in all LPS treated 
groups compared to their respective controls, and these differences were all statistically 
significant (Figure 10). When comparing between LPS treated groups, the average 
values for TNFα and IL-6 serum concentration were lowest in SPF[LPS] and highest in 
PS[LPS]. The average serum concentration of TNFα and IL-6 in CoH[LPS] was between 
	
 49 
these groups. CoH[LPS] demonstrated a higher average TNFα serum concentration at 
365.05 pg/mL compared to the average serum TNFα concentration in SPF[LPS] at 
244.32 pg/mL (Figure 10A). CoH[LPS] also displayed a higher average IL-6 
concentration at 1.03*105 pg/mL compared to the average IL-6 concentration of 6.2*104 
in SPF[LPS] mice (Figure 10B). The difference between CoH[LPS] and SPF[LPS] mice 
in serum cytokine concentration was not found to be statistically significant for TNFα 
(p=0.09) or IL6 (p=0.56). The difference between SPF[LPS] and PS[LPS] in TNFα and 
IL-6 concentration was found to be statistically significant (p=0.0004 and p<0.0001). 
Figure 10: Serum concentration of pro-inflammatory cytokines TNFα and IL-6 across LPS and PBS 


































































































































IV. CS treated CoH mice display an increased total cell number, neutrophil, and 
SPM count compared to CS treated SPF mice. 
 Lavage samples were collected from SPF and CoH mice 6 hours after intra-
peritoneal injection of CS. Collected cells were stained for neutrophils, SPMs, and LPMs. 
Stained samples were analyzed by flow cytometer. CS treated CoH mice (CoH[CS]) had 
increased total cell number, neutrophils, and small peritoneal macrophages compared to 
CS treated SPF mice (SPF[CS]) (Figure 11). The difference between CoH[CS] and 
SPF[CS] was found to be statistically significant for total cell number (p<0.0001), 
neutrophils (p=0.0001), and small peritoneal macrophages (p=0.0006). Large peritoneal 
macrophage counts were not substantially different between SPF[CS] and CoH[CS] and 
this difference was not found to be statistically significant (p=0.960). Large peritoneal 
macrophages were decreased in both SPF[CS] and CoH[CS] mice compared to their 
controls (Figure 11D). Differences between CS treated mice and control groups for large 
peritoneal macrophages were found to be statistically significant for both SPF (p<0.0001) 
and CoH (p<0.0001) mice. CS treated SPF and CoH mice showed elevated neutrophil 
counts compared to their respective controls (Figure 11B). Differences in neutrophil 
count between CS treated mice and their controls were statistically significantly for SPF 
(p=0.0087) and CoH (p<0.0001) populations. Differences in SPM count between CS 
treatment and control populations were found to be statistically significant in SPF mice 
(p=0.011) but not significant in CoH mice (p=0.085) (Figure 11C). CoH[CS] 
demonstrated a statistically significant increase in total cell number (p<0.0001) and 




Figure 11: Total cell number, neutrophil, small peritoneal macrophage and large peritoneal macrophage 








































































































































































 The results from baseline, endotoxemia, and cecal slurry experiments support 
three main conclusions. First, a statistically significant difference in total peritoneal cell 
number, neutrophils, and peritoneal macrophages between untreated SPF, CoH, and PS 
mice provides support for the conclusion that environmental pathogen exposure 
influences host immunity at baseline (Figure 7). Second, the observation that CoH mice 
demonstrate significantly higher elevations in total cell number, neutrophils, and SPMs 
following intra-peritoneal injection of cecal slurry when compared to SPF mice treated 
with CS, supports the conclusion that a higher environmental pathogen exposure in CoH 
mice contributes to a larger immune response in the peritoneum following CS injection 
compared to SPF mice treated with CS (Figure 11). Third, ELISA analysis of serum 
collected from mice treated with LPS supports the conclusion that raising mice in a SPF 
barrier facility contributes to a significantly lower pro-inflammatory cytokine response to 
intra-peritoneal injection of LPS compared to “dirty” PS mice given LPS (Figure 10). 
These differences observed in the immune composition and response between SPF, CoH 
and PS mice largely support a view held by Beura et al, Huggins et al, and others, that 
environmental pathogen exposure directly influences the degree of host immune response 





II. Influence of Environmental Pathogen Exposure on Resting Host Immunity 
 Results from our baseline experiments are consistent with the findings of previous 
studies comparing the immune composition of SPF mice to CoH and pet store mice. 
Untreated CoH mice showed a significantly higher level of neutrophils and macrophages 
within the peritoneum when compared to untreated SPF mice in our baseline experiments 
(Figure 7). This observed increase in innate immune cell presence within the peritoneum 
of CoH mice compliments the findings of a landmark study conducted by Beura et al, 
which found that untreated CoH mice have significantly higher levels of CD8+ cells 
within the spleen and lungs compared to untreated SPF mice.61 Moreover, the observation 
from our baseline experiments that untreated pet store mice display higher levels of 
neutrophils, macrophages, and total cell number in the peritoneum compared to SPF and 
CoH mice is consistent with previous experiments comparing the innate immunity of SPF 
mice to pet store mice.66 In a study comparing the spleens of SPF mice to pet store mice, 
Japp et al reported that pet store mice display 3 times more granulocytes and monocytes 
in the spleen than SPF mice.69 In a similar study comparing the spleens of SPF mice to 
spleens collected from wild mice captured in southern area of England, Abolins et al 
found that wild mice display a significantly greater number of macrophages as well as a 
larger proportion of T cells in the spleen compared to SPF mice.70 
 Our observation that innate immunity increases with greater environmental 
pathogen exposure is also supported by multiple prior studies comparing the innate 
immunity of SPF mice raised in barrier facilities to germ free (GF) mice raised in sterile 
environments.71 A study conducted by Khosravi et al found that GF mice had 
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significantly lower absolute numbers for macrophages, neutrophils and monocytes within 
the spleen compared to SPF mice raised in environments with comparatively greater 
pathogen exposure.72 Studies comparing the myeloid compartment in bone marrow from 
SPF and GF mice report a similar finding, where lower numbers of monocytes and 
granulocytes are observed in the bone marrow of GF mice compared to bone marrow 
collected from SPF mice.73 Our baseline experiments show increased host immunity in 
the peritoneum with increasing environmental pathogen exposure across SPF, CoH, and 
PS mice, and this is consistent with the findings of these studies comparing SPF mice to 
GF mice, as well as the previously described experiments comparing the innate immunity 
of SPF mice to pet store and feral mice.  
 
III. Environmental Pathogen Exposure and Host Immune Response to Cecal Slurry 
 The results of our CS experiment were also largely consistent with previous 
studies examining the inflammatory response of mice to cecal slurry injection. In our 
experiment, CoH mice demonstrated significantly higher elevations in total cell number, 
neutrophil, and SPM counts compared to SPF mice following intra-peritoneal injection of 
CS (Figure 11). Both CS and CLP models induce poly-microbial sepsis via introduction 
of commensal bacteria into the peritoneum. The larger infiltration of small peritoneal 
macrophages and neutrophils observed in CoH mice treated with CS compliments the 
findings from Huggins et al, who noted increased neutrophils and monocytes in the blood 
of CoH compared to SPF mice under a CLP model.62  
	
 55 
 Our CS experiment also demonstrates a well-documented septic response in mice 
following intra-peritoneal injection of CS. Multiple studies report an increased presence 
of neutrophils and blood-monocyte-derived macrophages within the peritoneum 
following intra-peritoneal injection of CS.74,75 Our study found a statistically significant 
increase in neutrophils and blood-monocyte-derived macrophages for both CoH and SPF 
mice treated with CS compared to PBS controls. Furthermore, our results from the CS 
experiment remain consistent with findings of previous studies when peritoneal 
macrophages are differentiated into the SPM and LPM subsets.  
 Previous studies have reported SPMs and LPMs as two phenotypically distinct 
subsets of peritoneal macrophages, where SPMs are differentiated from blood monocytes 
that enter the peritoneum from the vasculature during inflammation, and LPMs are 
resident macrophages of the peritoneum that make up roughly 90% of macrophages 
under baseline conditions.76,77 Flow analysis of our CS experiment demonstrates that CoH 
mice treated with CS experienced an increase in SPMs, while both SPF and CoH mice 
experience a decrease in LPMs following administration of CS (Figure 11). This 
observed infiltration of SPMs into the peritoneum of CoH mice following intra-peritoneal 
injection of LPS is consistent with the findings of Ghosn et al, who reported an increase 
in SPMs within the peritoneum of SPF mice following LPS injection.76 The observed 
decrease in large peritoneal macrophages after induction of sepsis in CoH and SPF mice 
is also consistent with prior studies, which detail a mass migration of LPMs to the 
omentum via retinoic acid and GATA-6 dependent pathways following the introduction 
of LPS within the peritoneal space.78  
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 Given the consistency of our CS experiment with previous studies, the statistically 
significant decrease in small peritoneal macrophages following CS injection in SPF mice 
was surprising, and differed from our expectation that SPMs and other immune cells 
would increase within the peritoneum of all mouse types as part of an inflammatory 
response to CS injection. However, this observed decrease in total cell number within CS 
treated SPF mice compared to their control was not statistically significant, and SPM 
counts were calculated using the same sample concentration that was used for calculating 
total cell number in lavage samples taken from SPF[CS] mice. It could be possible that 
this insignificant decrease in cell concentration exaggerated an otherwise insignificant 
decrease in frequency of SPMs between CS treated SPF mice and their controls; creating 
a statistically significant decrease in SPMs in CS treated SPF mice compared to their 
controls, when the actual difference between these groups is insignificant. 
Acknowledging these considerations, the results from our CS experiment are otherwise 
consistent with previous studies and support the view from prior studies that differences 




IV. Environmental Pathogen Exposure and Host Immune Response to LPS 
 Our ELISA analysis of TNFα and IL-6 concentrations within serum collected 
from LPS treated mice suggests that the murine cardiovascular immune response to LPS 
increases with increasing environmental pathogen exposure (Figure 10). This finding is 
somewhat consistent with the prior study conducted by Huggins et al, who reported 
significantly higher elevations of TNFα and IL-6 cytokines in the serum of CoH mice 
compared to SPF mice following intravenous administration of LPS.62 While our LPS 
experiments did not find this difference between CoH[LPS] mice and SPF[LPS] mice to 
be statistically significant for either TNFα or IL-6 serum concentrations, ELISA data 
from our LPS experiments do demonstrate that PS[LPS] mice have significantly higher 
elevations in serum TNFα and IL6 concentrations compared to SPF[LPS] mice (Figure 
10). Average TNFα and IL6 concentrations were also found to be higher in CoH mice 
than SPF mice, and this could suggest that CoH mice experience a greater inflammatory 
response to LPS in the blood compared to SPF mice. However, additional studies are 
required to confirm the significance of this difference between SPF and CoH mice.  
 When considering differences between LPS treated mice and their controls, 
ELISA data from our LPS experiments is largely consistent with the finding of previous 
experiments evaluating the murine serum cytokine response to LPS. ELISA analysis 
shows a statistically significant increase in both TNFα and IL6 concentration within the 
blood of SPF, CoH, and pet store mice following intra-peritoneal injection of LPS. Prior 
experiments conducted Remick et al and Villa et al report similar increases in serum 
TNFα and IL6 cytokines following intra-peritoneal injection of LPS, and Copeland et al 
	
 58 
also found a sharp increase in murine serum TNFα concentration following LPS 
administration in a comparison between human and murine inflammatory responses to 
LPS endotoxemia.79,80,81  
 On the other hand, flow cytometer analysis of lavage samples collected from LPS 
treated mice contrasts the results of previous studies on LPS endotoxemia and our own 
experiments in two notable ways. First, all differences observed between SPF[LPS], 
CoH[LPS], and PS[LPS] mice in total cell number, neutrophils, SPMs, and LPMs were 
found not to be statistically significant (Figure 11). When taken at face value, this result 
would suggest that environmental pathogen exposure does not significantly influence 
host response to LPS within the peritoneum. However, this conclusion requires careful 
consideration given the results of a previous study conducted by Huggins et al comparing 
the septic response of SPF and CoH mice to a bolus 10 kg/mg dose of LPS administered 
intravenously, which demonstrated a clear difference in septic mortality between SPF and 
CoH mice secondary to baseline serological differences between these groups in immune 
cell composition and pro-inflammatory cytokines.62 
 Furthermore, results from our baseline experiments demonstrate that untreated 
CoH and PS have higher absolute counts for neutrophils and macrophages in the 
peritoneum compared to SPF mice (Figure 7), suggesting that immunity within the 
peritoneum is influenced by prior environmental pathogen exposure. In a previous study, 
Katsuaki et al used knock-out TLR4 mice to demonstrate that LPS elicits a strong pro-
inflammatory response from innate immune cells through TLR4 dependent pathways.82 
Moreover, Huggins et al report that CoH mice have an increased number of TLR4 innate 
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immune cells with increased expression TLR4 compared to SPF mice.62 These previous 
findings, along with our baseline data between SPF, CoH, and PS mice, support the 
hypothesis that CoH mice should experience a larger infiltration of SPMs and neutrophils 
into the peritoneum following intra-peritoneal injection of LPS compared to SPF mice. 
However, when comparing between SPF[LPS], CoH[LPS] and PS[CoH] mice, a 
statistically insignificant but consistent trend in decreasing total cell number, SPM, and 
LPM counts was observed with increasing environmental pathogen exposure (Figure 9). 
 Perhaps most surprising, the second way in which flow cytometry results 
contrasted from previous studies was found when comparing LPS treated mice to their 
PBS controls for total cell number, SPMs, and LPMs. Although none of these differences 
were found to be statistically significant, a consistent trend in decreased total cell 
number, SPMs, and LPMs was observed in SPF[LPS], CoH[LPS] and PS[LPS] mice 
when compared to their respective PBS controls (Figures 9.A, 9.C and 9.D). Decreasing 
total cell count and SPMs in SPF, CoH, and PS mice after bolus administration of LPS 
sharply contrasts a core premise of the LPS endotoxemia model: that intra-peritoneal 
injection of LPS activates TLR-4 mediated inflammatory pathways and elicits an 
inflammatory response that includes cellular infiltration of neutrophils and blood 
monocytes into the peritoneum. Various studies on LPS endotoxemia have previously 
demonstrated that intra-peritoneal injection of LPS elicits an infiltration of neutrophils 
and SPMs into the peritoneum.79,83,84  
 Initial observation of these results between LPS treated mice and their PBS 
controls prior to completing ELISA analysis raised questions about the degree of 
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inflammation within the peritoneum of these mice. However, the comparison of blood 
samples taken from LPS treated mice and their controls showed statistically significant 
elevations in TNFα and IL-6 serum concentrations for all LPS treated groups, while 
serum concentrations of TNFα and IL-6 were largely undetectable in mice given PBS 
(Figure 10). Given that serum IL-6 cytokine levels are considered to be a sensitive test 
for the presence of inflammation, these results from our ELISA data provide convincing 
evidence that an exclusive inflammatory response occurred in the blood of mice given 
LPS that was not present in controls treated with PBS.85 Following these results from our 
ELISA analysis, the decreased total cell number and SPMs observed in SPF, CoH, and 
PS mice following LPS treatment raised questions about the nature of the inflammatory 
response to LPS injection in these mice. 
 Prior studies report that activated macrophages are a primary producer of both 
TNFα and IL6 cytokines, and these cytokines, particularly TNFα, are known to further 
stimulate inflammatory responses from macrophages and monocytes.86,87 Acknowledging 
the statistically insignificant but consistent decrease in SPMs and total cell number within 
the peritoneum of mice following treatment with LPS, the elevated serum concentrations 
of these pro-inflammatory cytokines could reflect the infiltration of monocytes and their 
differentiation into active macrophages within other tissue compartments outside of the 
peritoneum. Although a mass infiltration of innate immune cells including blood 
monocytes to the site of LPS administration is expected given, mass migration of immune 
cells to different areas of the body following intra-peritoneal administration of LPS has 
also been reported by previous studies. In a study evaluating mechanisms of sepsis 
	
 61 
mortality, McDonald et al found that neutrophils migrate to the capillaries of the lung and 
liver following LPS administration, and undergo NETosis after their interaction with 
activated platelets in the blood.88 This phenomenon is reported to increase bacterial 
clearance from the blood at the cost of increased damage to the local tissue secondary to 
cytotoxic granule release from neutrophils.89,90 Although the results of our LPS 
experiments are more consistent with an infiltration of blood monocytes into a tissue 
compartment outside of the peritoneal space following LPS administration, previous 
studies on intra-peritoneal injection of LPS demonstrate that neutrophils and SPMs 
infiltrate the peritoneum as part of the inflammatory response to LPS, and do not provide 
evidence to suggest that a mass migration of blood monocytes is occurring elsewhere. 
 
V. Comparison of Inflammatory Responses under CS and LPS Sepsis Models 
 Considerable differences in the peritoneal immune response of mice are observed 
when comparing LPS endotoxemia to the CS model (Figures 9 and 11). The significant 
difference in murine immune response between LPS and CS treated mice contrasts the 
findings of previous studies comparing septic models. A prior study conducted by 
Seeman et al found that LPS and CS models produce similar levels of immune cell 
infiltrate to the liver following induction of sepsis, and concluded that the CLP model 
differed most from other sepsis models.91 Furthermore, a comparison between LPS and 
CS experiments for trends in inflammatory immune response with environmental 
pathogen exposure also shows differences between these models. Our CS experiment 
demonstrated that CoH mice treated with CS experience an increased infiltration of 
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immune cells compared to treated SPF mice. The lack of a significant trend between LPS 
treated SPF, CoH, and PS mice would suggest that there is a difference in the degree of 
influence that previous environmental immune exposure has on TLR-4 specific, LPS-
induced inflammation versus poly-microbial CS-induced inflammation in the peritoneum. 
LPS mediated mechanisms are certainly involved in the inflammatory response of mice 
to CS injection, as the LPS antigen is present on most gram-negative bacteria, and gram-
negative bacteria are abundant in the cecal content used for CS experiments.92 However, 
since our LPS experiments do not provide any conclusive result on the relationship 
between environmental pathogen exposure and cellular infiltration into the peritoneum 
during sepsis, the statistically significant results between SPF[CS], CoH[CS], and PS[CS] 
mice from our CS experiment could suggest that inflammatory pathways outside of 
LPS/TLR4 are mainly responsible for this noticeable difference in inflammatory response 
to CS with changes in murine environmental exposure.  
 
VI. Future Directions 
 Future studies could either expand upon our inconclusive results from LPS 
experiments using the cohoused model, or consider alternative methods outside of 
cohoused mice to evaluate the influence of environmental factors on the murine immune 
response to inflammatory stimuli. Our LPS experiments found no significant difference 
between SPF and CoH mice in cellular infiltration or pro-inflammatory cytokine response 
following intra-peritoneal injection of LPS. Future studies could consider a different 
cellular/cytokine comparison between SPF and CoH mice through administration of LPS 
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at different doses to determine if this insignificant difference between SPF and CoH mice 
is secondary to LPS dosage. Additional studies could also expand upon the findings of 
McDonald et al, and monitor tissue compartments outside of the peritoneum to track the 
movement of blood monocytes following intra-peritoneal administration of LPS to 
evaluate whether or not data from our LPS experiments reflects the activity of blood 
monocytes in areas other than the peritoneum following LPS injection.88 
 Alternatively, future studies could consider models of microbial exposure outside 
of CoH mice to determine the influence of environmental pathogen exposure on murine 
septic immune response. Reese et al demonstrate that mice sequentially infected with 
influenza, the herpes virus, and intestinal helminths have significantly reduced serum 
cytokines and antibody responses to yellow fever virus vaccination.93 Peripheral blood 
samples collected from these mice were analyzed for gene expression and found to have 
more similarities to peripheral blood gene expression in pet store mice than SPF mice. A 
comparison between sequentially infected SPF mice and traditional SPF mice under LPS, 
CS, or CLP sepsis models could determine whether or not this model better replicates the 
septic response in humans compared to the SPF model. Embryo transfer of laboratory 
mice into wild mice is another promising alternative to SPF mice. In a study comparing 
traditional SPF mice to SPF mice born from wild mice via embryo transfer, Rosshart et al 
found that wild-mouse-born SPF mice had significantly higher levels of TNFα and IL6 at 
baseline than traditional SPF mice, and exhibited similar immune responses to humans 
during anti-TNFα treatement.94 This model shows promise for experiments on sepsis, and 
future studies could investigate its potential through comparing the inflammatory 
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response and mortality of wild-mouse-born SPF mice to traditional SPF mice under LPS, 





 The experiments described above were completed to identify potential differences 
between SPF and CoH mice in their immune response to LPS and CS within the 
peritoneum and potentially identify a cause for the increased mortality previously 
observed in CoH mice compared to traditional SPF mice. To that end, the results of these 
experiments were mixed. In our LPS experiments, differences in cellular infiltration 
between SPF, CoH and PS mice following LPS administration was not significant and 
immune cell infiltration was lower in CoH and PS mice compared to SPF mice. This 
finding does not confirm the hypothesis that increased cellular infiltration into the 
peritoneum of CoH mice following LPS leads to increases in inflammatory response and 
subsequent mortality. However, collected blood samples show significantly higher pro-
inflammatory cytokines in PS mice compared to SPF mice following LPS administration, 
and this supports the potential for CoH mice to experience an increased inflammatory 
response to LPS within the blood compared to SPF mice.  
 Baseline experiments show a statistically significant increase in total cell number, 
neutrophils, and peritoneal macrophages within CoH mice compared to SPF mice, which 
support the view that CoH mice have noticeably different immune systems from SPF 
mice secondary to increased environmental pathogen exposure, and confirm their 
potential as an alternative to SPF mice for modeling sepsis in human beings. 
Furthermore, our CS experiment shows that CoH mice experience a significantly higher 
elevation in peritoneal immune response to CS injection when compared to SPF mice, 
and this finding may provide clues into the increased mortality of CoH mice observed by 
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Huggins et al following CLP, as both CS and CLP models work to introduce commensal 
bacteria to the peritoneum from the cecum. Additional studies should be completed to 
investigate whether the cause of increased CoH death to sepsis is related to increased 
damage secondary to differences in intra-peritoneal inflammation, or other phenomenon 
such as the previously reported mass migration of neutrophils and NETosis within the 
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